Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 26, Issue 9, 2013, Pages 926-931

  Carbonell Estrany, Xavier ^a   Fullarton, John R ^b   Gooch, Katherine L ^c   Vo, Pamela G ^c   Figueras Aloy, Jose ^a   Lanari, Marcello ^d   Gouyon, Jean Bernard ^e   Liese, Johannes G ^f  

^a HOSPITAL CLÍNIC   (Spain)

^b Strategen Limited   (United Kingdom)

^c ABBOTT LABORATORIES   (United States)

^d Hospital of Imola   (Italy)

^e University Hospital   (France)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bronchiolitis; Palivizumab; Premature infants; Risk factors; Tobacco

Indexed keywords

PALIVIZUMAB;

ARTICLE; ATOPY; BIRTH WEIGHT; BREAST FEEDING; CHILD HOSPITALIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FAMILY HISTORY; FRANCE; GERMANY; GESTATIONAL AGE; HOUSEHOLD; HOUSEHOLD SMOKING; HUMAN; INFANT; INFECTION RISK; ITALY; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; PARENTAL SMOKING; PREMATURITY; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK REDUCTION; WHEEZING;

ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; COHORT STUDIES; FAMILY CHARACTERISTICS; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PARENTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; TOBACCO SMOKE POLLUTION;

EID: 84877946295     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2013.765850     Document Type: Article

References (38)

1. Semple MG, Taylor-Robinson DC, Lane S, Smith RL. Household tobacco smoke and admission weight predict severe bronchiolitis in infants independent of deprivation: prospective cohort study. PLoS One 2011;6:e22425.
2. Carroll KN, Gebretsadik T, Griffin MR, et al. Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy. Pediatrics 2007;119:1104-12.
3. Hugg TT, Jaakkola MS, Ruotsalainen RO, et al. Parental smoking behaviour and effects of tobacco smoke on children's health in Finland and Russia. Eur J Public Health 2007;18:55-62.
4. Haberg SE, Stigum H, Nystad W, Nafstad P. Effects of pre-and postnatal exposure to parental smoking on early childhood respiratory health. Am J Epidemiol 2007;166:679-86.
5. Li Y-F, Gilliland FD, Berhane K, et al. Effects of in utero and environmental tobacco smoke exposure on lung function in boys and girls with and without asthma. Am J Respir Crit Care Med 2000;162:2097-104.
6. Jones LL, Hashim A, McKeever T, et al. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and metaanalysis. Respir Res 2011;12:5.
7. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-55.
8. Simões EAF, Rieger CHL. RSV infection in developed and developing countries. Infect Med 1999;16:24-30.
9. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncitial virus infection requiring hospitalisation in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23:815-20.
10. Law BJ, Langley JM, Allen U, et al. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalisation for respiratory syncitial virus infection for infants born at 33 through 35 completed weeks of gestational age. Pediatr Infect Dis J 2004;23:806-14.
11. Liese JG, Grill E, Munich RSV Study Group, et al. Incidence and risk factors of respiratory syncytial virus-related hospitalisations in premature infants in Germany. Eur J Pediatr 2003;162:230-6.
12. Rossi GA, Medici MC, Osservatorio RSV Study Group, et al. Osservatorio RSV Study Group. Risk factors for severe RSVinduced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007;166:1267-72.
13. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. Flip-2 Study. Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27:788-93.
14. Simões EAF. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003;143:S118-26.
15. McConnochie KM, Roghmann KJ. Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis. Am J Dis Child 1986;140:806-12.
16. Carbonell-Estrany X, Quero J; IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001; 20:874-9.
17. Carbonell-Estrany X, Quero J, Bustos G, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000;19:592-7.
18. Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991;133:1135-51.
19. Bulkow LR, Singleton RJ, Alaska RSV Study Group, et al. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002;109:210-6.
20. Feltes TF, Cabalka AK, Cardiac Synagis Study Group, et al. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40.
21. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
22. Simões EAF, Carbonell-Estrany X, Fullarton JR, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation in premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP study. Respir Res 2008;9:78.
23. Simões EA, Carbonell-Estrany X, The European RSV Risk Factor Study Group, et al. European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med 2011;24:152-7.
24. Carbonell-Estrany X, Simões EA, The European RSV Risk Factor Study Group, et al. Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation. J Perinat Med 2010;38:411-7.
25. Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simoes EA. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 2010;29:374-6.
26. Abbott Laboratories, Abbott Park, IL. Data on File. Study CP048. [last accessed Oct 2012].
27. Grimaldi M, Cornet B, Milou C, Gouyon JB. Prospective regional study of an epidemic of respiratory syncytial virus (RSV) bronchiolitis. [Article in French]. Arch Pediatr 2002; 9:572-80.
28. Medici MC, Arcangeletti MC, Osservatorio VRS Study Group, et al. Four-year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the "Osservatorio VRS" Study (2000-2004). New Microbiol 2006;29:35-43.
29. Lunn DJ, Thomas A, Best N, et al. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
30. MRC Biostatistics Unit, Cambridge, UK. The BUGS project. Available from: http://www.mrc-bsu.cam.ac.uk/bugs/[last accessed 18 May 2011].
31. SPSS Inc. 444 N. Michigan Avenue, Chicago, IL 60611.
32. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003; 143:S133-41.
33. Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89:673-8.
34. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003; 143:S150-6.
35. Willson DF, Landrigan CP, Horn SD, Smout RJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003;143:S142-9.
36. German Society for Paediatric Infectious Diseases Association (DGPI). Stellungnahme zur Prophylaxe von schweren RSVErkrankungen bei Risikokindern mit Palivizumab. Available from: www.dgpi.de [last accessed 01 Oct 2012].
37. Robinson JL; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing respiratory syncytial virus infections. Paediatr Child Health 2011;16:488-90.
38. American Academy of Pediatrics. Policy Statement-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1694-701.